Compare AbCellera Biologics Inc (ABCL) vs Hilton Hotels Corporation Common Stock (HLT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Hilton Hotels Corporation Common Stock — how do they compare? AbCellera Biologics Inc trades at $7.23 (market cap $2.35B), while Hilton Hotels Corporation Common Stock trades at $333.44 (market cap $77.66B). The key difference: Hilton Hotels Corporation Common Stock is far larger — about 33× AbCellera Biologics Inc's market cap, and Hilton Hotels Corporation Common Stock pays a 0.18% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | HLT | |
|---|---|---|
Market Cap | $2.35B | $77.66B |
Sector | Health | Consumer Cyclical |
52-Week High | $8.12 | $350.22 |
52-Week Low | $2.78 | $256.75 |
Enterprise Value | $1.99B | $90.15B |
Dividend Yield | — | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Hilton Worldwide (HLT) trades at $341.12, up 0.89% with strong technical momentum as price approaches resistance at $342. The stock shows consistent earnings beats with Q1 2026 EPS of $2.01 exceeding expectations of $1.98, while revenue growth continues from $12.04B in 2025 to projected $12.3B in 2026. Analyst consensus remains bullish with 55% buy ratings and a $342.11 price target closely aligned with current levels.
The outlook remains positive given Hilton's market leadership and sustained travel demand, though elevated debt levels and valuation multiples present risks. With technical indicators showing bullish momentum and strong institutional support, the stock appears positioned for continued growth, though investors should monitor debt management and competitive pressures in the hospitality sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Hilton Hotels Corporation Common Stock
Hilton Worldwide Holdings operates 1,074,791 rooms across its 18 brands addressing the midscale through luxury segments as of Dec. 31, 2021. Hampton and Hilton are the two largest brands by total room count at 28% and 21%, respectively, as of Dec. 31, 2021. Recent brands launched over the last few years include Home2, Curio, Canopy, Tru, and Tempo. Managed and franchised represent the vast majority of adjusted EBITDA, predominantly from the Americas regions.
Read more on HLT →
